Table 1.
Clinicopathological characteristics of HNSCC patients and the control group.
| Control Group | HNSCC Patients (Blood) | HNSCC Patients (Tumor Tissue) | |
|---|---|---|---|
| n (female/male) | 23 (13/10) | 23 (9/14) | 12 (5/7) |
| Age (±SD) range (y) | 56 ± 19 (27–84) | 59 ± 11 (37–74) | 67 ± 9 (49–77) |
| Stage (n) | |||
| T1 | 4 | 2 | |
| T2 | 8 | 6 | |
| T3 | 5 | 2 | |
| T4 | 6 | 2 | |
| Nodal status (n) | |||
| N0 | 7 | 2 | |
| N1 | 5 | 3 | |
| N2 | 7 | 7 | |
| N3 | 4 | 0 | |
| Location (n) | |||
| Oral cavity | 5 | 1 | |
| Oropharynx | 10 | 8 | |
| Hypopharynx | 4 | 1 | |
| Larynx | 4 | 2 | |
| PD-L1 status on tumor tissue (n) | |||
| 0% | 3 | ||
| ≥1% | 5 | ||
| ≥5% | 4 | ||
| PD-L1 Quickscore | |||
| 0 | 3 | ||
| 1 | 3 | ||
| 2 | 2 | ||
| 4 | 2 | ||
| 6 | 2 | ||
| HPV status | |||
| Positive | 7 | ||
| Negative | 16 | ||
| Overall survival at 3 y | 22/23 | ||
| Disease-free survival at 3 y | 21/23 |